Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Vitis vinifera fraction 1** is an experimentally studied **polyphenol-enriched botanical extract** isolated from the pulp and skin of seedless black *Vitis vinifera* fruit. It has been evaluated in academic preclinical models as a hepatoprotective and anticancer research agent, particularly in hepatotoxicity and hepatocellular carcinoma settings. Reported activity appears to be multi-mechanistic rather than directed at a single defined molecular target, with effects that include antioxidant and anti-inflammatory activity, reduction of necroptosis-associated signaling, suppression of pro-fibrotic mediators such as mixed lineage kinase domain-like protein, collagen type I alpha 1 chain, and transforming growth factor beta 1, and induction of apoptosis in liver cancer models. Available evidence is limited to preclinical research, with no identified commercial sponsor, marketed product, or established pharmaceutical development program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitis vinifera fraction 1.